Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastrointestinal Cancer

Urothelial Cancer

Prostate Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Axatilimab induced rapid and durable responses with an acceptable toxicity profile at all doses analyzed with highest efficacy observed at the 0.3-mg/kg dose in patients with recurrent or refractory chronic graft-vs-host disease.

Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD

Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.


Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma

Paolo Ghia, MD, PhD, full professor, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial investigating zanubrutinib vs bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.


Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL

Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome. 

Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements And Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Print Subscription

eNewsletter

joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

, and now serves as the main digital news writer for 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

A new artificial intelligence tool may make it possible to spare breast cancer patients unnecessary chemotherapy treatments by using a more precise method of predicting their outcomes.

AI May Spare Breast Cancer Patients Unnecessary Treatments

Odronextamab produced durable responses and a generally manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma. 

Odronextamab Exhibits Continued Clinical Activity and Tolerable Safety Profile in R/R DLBCL

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

2024 nominations are open for Giants of Cancer Care® 

In-person and virtual events just for HCPs

REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Share your views with OncChats 

Specialty

Authors

Alex E. Denes, MD, associate professor of medicine, School of Medicine, Oregon Health and Science University, discusses biosimilar pricing in oncology.
 

Dr. Denes Discusses Biosimilar Pricing in Oncology

Alex E. Denes, MD, associate professor of medicine, School of Medicine, Oregon Health and Science University, discusses the use of biosimilars in the treatment of patients with cancer.

Dr. Denes on the Use of Biosimilars in Oncology

Alex E. Denes, MD

Articles

Latest Conference Coverage